Katherine Lord1, Enyo Dzata, Kara E Snider, Paul R Gallagher, Diva D De León. 1. MD, Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, 3615 Civic Center Boulevard, Abramson Research Center Room 802A, Philadelphia, Pennsylvania 19104. deleon@email.chop.edu.
Abstract
CONTEXT: Congenital hyperinsulinism (HI) occurs in two distinct histologic forms: diffuse and focal. Distinguishing between them is essential because a pancreatectomy is curative for focal HI and palliative for diffuse HI. OBJECTIVE: The purpose of this study was to compare the presentations, treatment, and outcomes of diffuse and focal HI. DESIGN: A retrospective chart review of children who underwent pancreatectomy for hyperinsulinism from December 2004 through September 2012 was conducted. RESULTS: Based on pancreatic histology, 223 children were classified into 3 groups: diffuse (n = 97, 44%), focal (n = 114, 51%), and other (n = 12, 5%). Children with diffuse vs focal HI had significantly different mean gestational ages (38 vs 39 weeks, P < .0005) and birth weights (3963 vs 3717 g P = .012). Children with focal HI presented at an older age (0.3 vs 0 months, P < .0005) and more frequently with seizures (50 vs 25%, P < .0005). Children with diffuse HI had higher insulin levels during hypoglycemia (31.8 vs 12 μU/mL, P < .0005) and required higher glucose infusion rates (19.2 vs 16.1 mg/kg/min, P = .002). Children with diffuse HI had a median percent pancreactectomy of 98%, and postoperatively 41% required treatment for continued hypoglycemia. Children with focal HI had a median percent pancreatectomy rate of 27%, and 94% required no treatment after surgery. CONCLUSIONS: Focal and diffuse HI present unique challenges, but the clinical differences between the 2 are subtle. Children with focal HI are at higher risk of delayed diagnosis and hypoglycemic seizures, but most are cured with surgery. In contrast, children with diffuse disease may be identified earlier, but face ongoing blood glucose abnormalities.
CONTEXT: Congenital hyperinsulinism (HI) occurs in two distinct histologic forms: diffuse and focal. Distinguishing between them is essential because a pancreatectomy is curative for focal HI and palliative for diffuse HI. OBJECTIVE: The purpose of this study was to compare the presentations, treatment, and outcomes of diffuse and focal HI. DESIGN: A retrospective chart review of children who underwent pancreatectomy for hyperinsulinism from December 2004 through September 2012 was conducted. RESULTS: Based on pancreatic histology, 223 children were classified into 3 groups: diffuse (n = 97, 44%), focal (n = 114, 51%), and other (n = 12, 5%). Children with diffuse vs focal HI had significantly different mean gestational ages (38 vs 39 weeks, P < .0005) and birth weights (3963 vs 3717 g P = .012). Children with focal HI presented at an older age (0.3 vs 0 months, P < .0005) and more frequently with seizures (50 vs 25%, P < .0005). Children with diffuse HI had higher insulin levels during hypoglycemia (31.8 vs 12 μU/mL, P < .0005) and required higher glucose infusion rates (19.2 vs 16.1 mg/kg/min, P = .002). Children with diffuse HI had a median percent pancreactectomy of 98%, and postoperatively 41% required treatment for continued hypoglycemia. Children with focal HI had a median percent pancreatectomy rate of 27%, and 94% required no treatment after surgery. CONCLUSIONS: Focal and diffuse HI present unique challenges, but the clinical differences between the 2 are subtle. Children with focal HI are at higher risk of delayed diagnosis and hypoglycemic seizures, but most are cured with surgery. In contrast, children with diffuse disease may be identified earlier, but face ongoing blood glucose abnormalities.
Authors: C Sempoux; C Capito; C Bellanné-Chantelot; V Verkarre; P de Lonlay; Y Aigrain; C Fekete; Y Guiot; J Rahier Journal: J Clin Endocrinol Metab Date: 2011-09-28 Impact factor: 5.958
Authors: P de Lonlay; J C Fournet; J Rahier; M S Gross-Morand; F Poggi-Travert; V Foussier; J P Bonnefont; M C Brusset; F Brunelle; J J Robert; C Nihoul-Fékété; J M Saudubray; C Junien Journal: J Clin Invest Date: 1997-08-15 Impact factor: 14.808
Authors: K E Snider; S Becker; L Boyajian; S-L Shyng; C MacMullen; N Hughes; K Ganapathy; T Bhatti; C A Stanley; A Ganguly Journal: J Clin Endocrinol Metab Date: 2012-12-28 Impact factor: 5.958
Authors: P M Thomas; G J Cote; N Wohllk; B Haddad; P M Mathew; W Rabl; L Aguilar-Bryan; R F Gagel; J Bryan Journal: Science Date: 1995-04-21 Impact factor: 47.728
Authors: V Verkarre; J C Fournet; P de Lonlay; M S Gross-Morand; M Devillers; J Rahier; F Brunelle; J J Robert; C Nihoul-Fékété; J M Saudubray; C Junien Journal: J Clin Invest Date: 1998-10-01 Impact factor: 14.808
Authors: Changhong Li; Amanda M Ackermann; Kara E Boodhansingh; Tricia R Bhatti; Chengyang Liu; Jonathan Schug; Nicolai Doliba; Bing Han; Karen E Cosgrove; Indraneel Banerjee; Franz M Matschinsky; Itzhak Nissim; Klaus H Kaestner; Ali Naji; N Scott Adzick; Mark J Dunne; Charles A Stanley; Diva D De León Journal: Diabetes Date: 2017-04-25 Impact factor: 9.461
Authors: C Saint-Martin; Q Zhou; G M Martin; C Vaury; G Leroy; J-B Arnoux; P de Lonlay; S-L Shyng; C Bellanné-Chantelot Journal: Clin Genet Date: 2014-06-06 Impact factor: 4.438
Authors: Katherine Lord; Jerilynn Radcliffe; Paul R Gallagher; N Scott Adzick; Charles A Stanley; Diva D De León Journal: J Clin Endocrinol Metab Date: 2015-09-01 Impact factor: 5.958
Authors: Puja Patel; Lawrenshey Charles; John Corbin; Ira D Goldfine; Kirk Johnson; Paul Rubin; Diva D De León Journal: MAbs Date: 2018-06-01 Impact factor: 5.857